CTP-Conjugated Polypeptides Extend Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polypeptides, such as growth hormone and erythropoietin, have short circulatory half-lives due to susceptibility to denaturation and enzymatic degradation, leading to frequent dosing and reduced pharmacological efficacy, with existing technologies failing to enhance stability and immune response safety.
Innovation Solution
Conjugating chorionic gonadotropin carboxy-terminal peptides (CTPs) to the amino and carboxy termini of growth hormone, optionally with a signal peptide, to extend half-life and reduce dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides are administered frequently to maintain therapeutic levels, then pharmacological efficacy is maintained, but patient comfort deteriorates and dosing complexity increases
Solution Approach 1:
The patent applies dynamics by making the polypeptide's circulatory half-life variable through structural modification. By attaching carboxy-terminal peptides of chorionic gonadotrophin to the polypeptide, the half-life is dynamically extended from several hours to several days, allowing the drug to maintain therapeutic levels for longer periods without frequent administration.
Solution Approach 2:
The patent changes the physical and chemical parameters of the polypeptide by conjugating carboxy-terminal peptides of chorionic gonadotrophin to it. This parameter change increases the molecular weight and alters the pharmacokinetic properties, resulting in extended circulatory half-life and reduced dosing frequency while maintaining therapeutic efficacy.
2Reliability
If polypeptides are administered by frequent infusion, then therapeutic levels are maintained, but treatment complexity increases
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the polypeptide through chemical conjugation with carboxy-terminal peptides of chorionic gonadotrophin. This modification extends the circulatory half-life from hours to days, transforming the administration regimen from frequent infusions to less frequent injections, thereby reducing treatment complexity.
3Duration of action of moving object
If polypeptide half-life is extended through modification, then dosing frequency is reduced, but molecular structure complexity increases
Solution Approach 1:
The patent creates a composite polypeptide structure by conjugating carboxy-terminal peptides of chorionic gonadotrophin to the therapeutic polypeptide. This composite structure combines the therapeutic activity of the original polypeptide with the half-life extending properties of the chorionic gonadotrophin CTP, achieving extended duration of action through structural composition rather than complex engineering.
Data Source
AI summary
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.